Information Provided By:
Fly News Breaks for May 11, 2016
MDXG
May 11, 2016 | 07:24 EDT
Brean Capital updated its model on MiMedx using the company's updated guidance. The firm's estimates are at the low end of the range but noted it is still modeling revenue growth of just under 30%. Brean Capital reiterated its Buy rating and $12 price target on MiMedx shares.